Bio in GENERAL
JUST SAYING....
Wall Street Titan : Buying existing drugs and marking up the prices is no longer a viable long-term business plan given the political climate. There are two ways a pharma company can go, invest in R&D or acquire the promising pipelines of competitors. Gilead and Pfizer will need to do both to sustain their business as patents expire and generics come to the market.
Read more: http://seekingalpha.com/article/400...ble-state-biotech?source=nasdaq#ixzz4M0WyMyIT
Latest news on biotechnology conference, page-62
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
